1762 — Chunghwa Chemical Synthesis & Biotech Co Income Statement
0.000.00%
Last trade - 00:00
- TWD3.30bn
- TWD4.09bn
- TWD2.09bn
- 50
- 38
- 32
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,157 | 1,544 | 1,935 | 2,117 | 2,086 |
Cost of Revenue | |||||
Gross Profit | 469 | 687 | 949 | 962 | 757 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 1,036 | 1,275 | 1,496 | 1,654 | 1,806 |
Operating Profit | 121 | 269 | 438 | 464 | 281 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 144 | 650 | 498 | 583 | 333 |
Provision for Income Taxes | |||||
Net Income After Taxes | 117 | 532 | 401 | 466 | 265 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 117 | 532 | 401 | 466 | 265 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 117 | 532 | 401 | 466 | 265 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.5 | 3.17 | 5.12 | 5.94 | 3.39 |
Dividends per Share |